(Q36914985)

17 August 2017

1 reference

title

How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer (English)

1 reference

17 August 2017

Martin Schlumberger

1

1 reference

17 August 2017

Marcel Ricard

series ordinal

2

1 reference

17 August 2017

Gérard De Pouvourville

series ordinal

3

1 reference

17 August 2017

Furio Pacini

series ordinal

4

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Nature Clinical Practice Endocrinology and Metabolism

17 August 2017

published in

1 reference

17 August 2017

volume

3

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

641-650

1 reference

Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Management guidelines for patients with thyroid nodules and differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Cloning of the Human Thyrotropin β-Subunit Gene and Transient Expression of Biologically Active Human Thyrotropin after Gene Transfection

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

131I therapy for elevated thyroglobulin levels

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0594

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0594

1 reference

17 August 2017

1 reference